Related Experiment Videos
Mycobacteria, cytokines and antibiotics
1Department of Medical Microbiology, University College and Middlesex School of Medicine, School of Pathology, London.
Pathologie-Biologie
|April 1, 1990
Summary
Understanding immunity to mycobacteria remains a challenge, with current approaches potentially causing harm. New strategies focus on host response modulation to reawaken dormant tuberculosis persister bacteria and enhance protective immunity.
Area of Science:
- Immunology
- Microbiology
- Infectious Diseases
Background:
- The precise mechanisms of human immunity against mycobacteria, particularly Mycobacterium tuberculosis, are not fully understood.
- Current knowledge suggests that pathways involving gamma interferon, 1,25(OH)2 vitamin D3, and TNF release may contribute to immunopathology rather than protection.
- A significant clinical challenge is the presence of "persister" bacteria, which survive despite reduced bacterial load during therapy.
Purpose of the Study:
- To explore new therapeutic strategies for tuberculosis (TB) by focusing on modulating the host immune response.
- To address the challenge posed by dormant "persister" Mycobacterium tuberculosis bacilli that evade current treatments.
- To identify objectives for novel therapies, including reawakening dormant bacteria, enhancing immune recognition, and mitigating immunopathology.
Main Methods:
- This study is primarily a conceptual and strategic review, synthesizing existing knowledge on mycobacterial immunity and host-pathogen interactions.
- It analyzes the limitations of current understanding and therapeutic approaches.
- It proposes future directions for TB treatment based on host-directed immune modulation.
Main Results:
- Existing knowledge suggests that current immune pathways may inadvertently promote disease rather than cure.
- The existence of dormant "persister" bacteria is a major obstacle to complete eradication of Mycobacterium tuberculosis.
- Developing antibiotics to rapidly kill dormant bacilli is considered unlikely.
Conclusions:
- New therapeutic strategies for tuberculosis must shift focus from direct bacterial killing to modulating the host immune response.
- Effective host-directed therapies should aim to reawaken dormant persisters, improve their immune recognition, suppress damaging inflammatory pathways, and enhance protective immunity.
- Further research is needed to define the optimal protective immune mechanisms against Mycobacterium tuberculosis.